Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Product (Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Rhenium (Re-186), Yttrium (Y-90), Fluorine-18 (18F-FDG), Rubidium (Rb-82), Others), Application (Radiology, Interventional Radiology, Interventional Cardiology, Others), Procedure (X-ray/CT, Magnetic Resonance Imaging (MRI), Ultrasound, Others), End User (Hospitals, Research and Academic Institutes, Diagnostic Imaging Centers, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights of Diagnostic Radiopharmaceuticals and Contrast Media
Diagnostic radiopharmaceuticals and contrast media market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to grow at a CAGR of 6.30% in the above-mentioned forecast period.
Diagnostic radiopharmaceuticals are basically the molecules containing a drug attached with a radioisotope targeted toward a certain tissue/organ for diagnosis as well as treatment of diseases such as cancer, cardiovascular diseases, and hyperthyroidism. Radiopharmaceuticals are being extensively used in a technique called molecular imaging as biomarkers for specific molecular procedures that determine the onset and/or growth of a disease.
The rising cases of cancer and the increasing healthcare infrastructure are the significant factors responsible for driving the growth of the diagnostic radiopharmaceuticals and contrast media market. Additionally, the technological advancements in the minimally invasive therapeutic procedures also heighten the overall growth of the market. However, the high cost along with various stringent government regulations for production, storage, and usage and the high cost of equipment installation as well as their repair obstruct the market’s growth.
The growing research activities coupled with new product launches are expected to generate profitable opportunities for the market. On the other hand, the complications associated with diagnostic radiopharmaceuticals and contrast media procedures have the potential to challenge for the market’s growth.
This diagnostic radiopharmaceuticals and contrast media market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research diagnostic radiopharmaceuticals and contrast media market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Diagnostic Radiopharmaceuticals and Contrast Media Market Scope and Market Size
Diagnostic radiopharmaceuticals and contrast media market is segmented on the basis of product, application, procedure and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of product, the diagnostic radiopharmaceuticals and contrast media market is segmented into technetium (tc-99m), thallium (tl-201), gallium (ga-67), iodine (i-123), rhenium (re-186), yttrium (y-90), fluorine-18 (18f-fdg), rubidium (rb-82) and others.
- On the basis of application, the diagnostic radiopharmaceuticals and contrast media market is segmented into radiology, interventional radiology, interventional cardiology and others.
- On the basis of procedure, the diagnostic radiopharmaceuticals and contrast media market is segmented into X-RAY/CT, magnetic resonance imaging (MRI), ultrasound and others.
- On the basis of end user, the diagnostic radiopharmaceuticals and contrast media market is segmented into hospitals, research and academic institutes, diagnostic imaging centers and others.
Diagnostic Radiopharmaceuticals and Contrast Media Market Country Level Analysis
Diagnostic radiopharmaceuticals and contrast media market is analyzed and market size insights and trends are provided by product, application, procedure and end user as referenced above.
The countries covered in the diagnostic radiopharmaceuticals and contrast media market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to highly developed healthcare system and large numbers of major national clinical laboratories and easy access to technologically advanced equipment. Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period owing to the rising cases of cancer and the increasing healthcare infrastructure.
The country section of the diagnostic radiopharmaceuticals and contrast media market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Diagnostic radiopharmaceuticals and contrast media market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for diagnostic radiopharmaceuticals and contrast media market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the diagnostic radiopharmaceuticals and contrast media market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Diagnostic Radiopharmaceuticals and Contrast Media Market Share Analysis
Diagnostic radiopharmaceuticals and contrast media market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to diagnostic radiopharmaceuticals and contrast media market.
Some of the major players operating in the diagnostic radiopharmaceuticals and contrast media market report are Cardinal Health, Curium, GENERAL ELECTRIC COMPANY, Lantheus Medical Imaging, Inc., Bayer AG, Bracco Diagnostic Inc., Eczacibasi Monrol, Nordion (Canada) Inc., Advanced Accelerator Applications, NTP, Mallinckrodt., Eli Lilly and Company, Jubilant Pharma Limited, Actinium Pharmaceuticals, Inc., Merck & Co., Inc., Navidea Biopharmaceuticals, Inc., Eckert & Ziegler., Siemens Healthcare Private Limited, Novartis AG, and Beijing International Pharmaceutical Technology Co., Ltd., among others.
SKU-